Monopar Therapeutics Inc. Sale of Stock, Consideration Received on Transaction
Monopar Therapeutics Inc. (MNPR) reported Sale of Stock, Consideration Received on Transaction of $823.86 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2023-05-11
- Monopar Therapeutics Inc. sale of stock, consideration received on transaction for the quarter ending 2023-03-31 was $823.86K.
- Monopar Therapeutics Inc. sale of stock, consideration received on transaction for the quarter ending 2021-12-31 was $1.00.
- Monopar Therapeutics Inc. sale of stock, consideration received on transaction for the quarter ending 2021-03-31 was $19.10M.
- Monopar Therapeutics Inc. sale of stock, consideration received on transaction for fiscal 2022 was $170.55K.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 12 month | Sale of Stock, Consideration Received on Transaction 18 month | Sale of Stock, Consideration Received on Transaction 21 month | Sale of Stock, Consideration Received on Transaction 24 month |
|---|---|---|---|---|---|
| 2023-03-31 | $823.86K 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $170.55K 10-K · filed 2023-03-23 | ||||
| 2021-12-31 | $1.00 derived: 10-K 24 month − 10-Q 21 month · filed 2023-03-23 | $19.10M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $19.10M 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $19.10M 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $19.10M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |